HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women.
OBJECTIVE This study was undertaken to examine the effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women . STUDY DESIGN Analysis of data from a multicenter , r and omized , double-blind , placebo-controlled trial of a 0.014 mg/day transdermal estradiol patch in 417 women aged 60 to 80 years . Sexual function was assessed by self-administered question naires at baseline and 4 , 12 , and 24 months . A linear effects model was used to assess treatment effects using data from all on- study assessment s. RESULTS Women r and omly assigned to estradiol had a 4.3 point greater improvement in the vaginal pain/dryness domain relative to placebo ( 95 % CI = 0.3 - 8.4 , P = .04 ) . No significant differences in frequency of sexual activity or other sexual function domains ( desire , satisfaction , problems , or orgasm ) were observed between treatment groups ( P > or = .10 for all ) . CONCLUSIONS Ultralow-dose estradiol result ed in modest improvement in sexual function related to vaginal pain and dryness , but not in other domains of sexual function
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .